Daniel Brennan, EVP and CFO of Boston Scientific Corp (BSX, Financial), sold 13,662 shares of the company on February 20, 2024, according to a recent SEC Filing. Boston Scientific Corp is a global medical technology leader, innovating to meet the needs of healthcare professionals and patients. The company develops, manufactures, and markets a broad range of medical devices that are used in a variety of interventional medical specialties.
Over the past year, the insider has sold a total of 119,272 shares and has not made any purchases of the company's stock.
The insider transaction history for Boston Scientific Corp shows a pattern of selling activity, with 0 insider buys and 38 insider sells over the past year.
On the day of the insider's recent sale, shares of Boston Scientific Corp were trading at $65.86, resulting in a market cap of $97.011 billion.
The stock's price-earnings ratio stands at 61.89, which is above the industry median of 27.24 but below the company's historical median price-earnings ratio.
With a trading price of $65.86 and a GuruFocus Value of $52.81, Boston Scientific Corp has a price-to-GF-Value ratio of 1.25, indicating that the stock is considered Modestly Overvalued according to the GF Value metric.
The GF Value is calculated based on historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
